PHARMACOKINETICS AND EXPOSURE-RESPONSE ANALYSES OF TELISOTUZUMAB VEDOTIN IN PATIENTS WITH ADVANCED SOLID TUMORS: PRELIMINARY PHASE I RESULTS.

被引：0
|
作者：
Parikh, A. [1 ]
Menon, R. [2 ]
Afar, D. [1 ]
Naumovski, L. [1 ]
Friedel, A. [3 ]
Kasichayanula, S. [1 ]
Mensing, S. [3 ]
机构：
[1] AbbVie Inc, Redwood City, CA USA
[2] AbbVie Inc, N Chicago, IL USA
[3] AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2019年 / 105卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-085
引用
收藏
页码：S67 / S67
页数：1
相关论文
共 50 条
  • [1] Preliminary Results of Safety and PK of Telisotuzumab Vedotin (T) in Japanese Patients with Advanced Solid Tumors
    Murakami, Haruyasu
    Wakuda, Kazushige
    Kenmotsu, Hirotsugu
    Todaka, Akiko
    Yokota, Tomoya
    Yamamoto, Noboru
    Shimizu, Toshio
    Shimomura, Akihiko
    Yonemori, Kan
    Ocampo, Christopher
    Parikh, Apurvasena
    Fukasawa, Kazuteru
    Matsumoto, Ikiru
    Suzuki, Koji
    Fujiwara, Yutaka
    ANNALS OF ONCOLOGY, 2019, 30 : 125 - 125
  • [2] Phase 1 study of telisotuzumab vedotin in Japanese patients with advanced solid tumors
    Fujiwara, Yutaka
    Kenmotsu, Hirotsugu
    Yamamoto, Noboru
    Shimizu, Toshio
    Yonemori, Kan
    Ocampo, Christopher
    Parikh, Apurvasena
    Okubo, Sumiko
    Fukasawa, Kazuteru
    Murakami, Haruyasu
    CANCER MEDICINE, 2021, 10 (07): : 2350 - 2358
  • [3] Population pharmacokinetic and exposure-response safety analyses of mecbotamab vedotin (BA3011) in patients with advanced solid tumors
    Shen, Guoxiang George
    Briggs, Emily
    Crass, Ryan
    Karumanchi, Sravan
    Boyle, William J.
    Baker, Michael G.
    Martin, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Efficacy and safety exposure-response analyses of entrectinib in patients with advanced or metastatic solid tumors
    Mercier, Francois
    Djebli, Nassim
    Gonzalez-Sales, Mario
    Jaminion, Felix
    Meneses-Lorente, Georgina
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (03) : 363 - 372
  • [5] Population pharmacokinetic and exposure-response analyses of pemigatinib in patients with advanced solid tumors including cholangiocarcinoma
    Gong, Xiaohua
    Akil, Ayman
    Ndi, Andre
    Ji, Tao
    Liu, Xiang
    Lovern, Mark
    Chen, Xuejun
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2023, 12 (11): : 1784 - 1794
  • [6] Tislelizumab exposure-response analyses of efficacy and safety in patients with advanced tumors
    Wu, C-Y.
    Budha, N.
    Gao, Y.
    Castro, H.
    Nkobena, A.
    Ben, Y.
    Sahasranaman, S.
    ANNALS OF ONCOLOGY, 2019, 30 : 182 - +
  • [7] PRELIMINARY PHASE 1 PHARMACOKINETIC (PK) AND EXPOSURE-RESPONSE (ER) ANALYSES RESULTS OF ABBV-085, AN ANTIBODY DRUG CONJUGATE (ADC), IN PATIENTS WITH ADVANCED SOLID TUMORS.
    Polepally, A.
    Gopalakrishnan, S.
    Robinson, R.
    Myzak, M.
    Demetri, G.
    Villalobos, V.
    Menon, R.
    Kasichayanula, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S99 - S99
  • [8] Tepotinib Exposure-Response Analyses of Safety and Efficacy in Patients with Solid Tumors
    Xiong, W.
    Hietala, S.
    Nyberg, J.
    Papasouliotis, O.
    Anziano, R.
    Berghoff, K.
    Johne, A.
    Girard, P.
    Strotmann, R.
    Paik, P.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S36 - S36
  • [9] Population Pharmacokinetics and Exposure-Response Relationship of Zimberelimab in Chinese Patients with Advanced Tumors
    Yang, Fang
    Lu, Yongying
    Bai, Lihui
    Deng, Chenhui
    Liu, Zhen
    Sun, Zhihua
    Li, Li
    Wang, Shicong
    Zhou, Li
    Feng, Haifeng
    Yan, Shaoyu
    Zhu, Jiman
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (08): : 897 - 906
  • [10] Pharmacokinetics, pharmacodynamics and exposure response analyses of osemitamab in patients with locally advanced or metastatic solid tumors
    Shen, L.
    Yao, J.
    Chen, D.
    Yu, M.
    Lin, X-A.
    Qi, C.
    Xia, Z.
    Zhang, L.
    Yu, S.
    Germa, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S872 - S872
12345